Latest Market research report on Gastrointestinal Drugs Market is an in-depth research and analysis of the market by our industry size, share, growth, and trends and forecast to 2028. The report covers a vast expanse of information including an overview, comprehensive analysis, definitions and classifications, applications, and expert opinions, among others. With the extent of information filled in the report, the presentation and style of the Gastrointestinal Drugs Market report is a noteworthy.
Gastrointestinal (GI) disorders are the medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders include constipation, irritable bowel, ulcerative colitis, and peptic ulcer diseases. These disorders are characterized by various symptoms, such as pain, bloating, diarrhea, nausea, and vomiting. These disorders constitute a large proportion of outpatients and frequent hospital visits globally. A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rise in investments in the development of biologics and emergence of biosimilars are expected to drive the growth of the market in the forecast period.
Top Companies Analysis-
Sanofi
GlaxoSmithKline plc
Johnson and Johnson Services, Inc
Bausch Health
AstraZeneca
Takeda Pharmaceutical Company Limited
AbbVie Inc
Bayer AG
Celltrion Healthcare Co., Ltd
Gastrointestinal diseases are the conditions that occur in the gastrointestinal tract. Common digestive problems include heartburn, inflammatory bowel diseases (IBD), inflammatory bowel syndrome (IBS), constipation, and diarrhea. GI diseases account for substantial health care utilization and spending. According to the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA), around 10 million people are living with IBD worldwide. Growing prevalence of IBD can be ascribed to poor nutritional choices, including a high intake of ultra-processed foods and trans-fats.
Western countries, such as the US, Canada, and the UK, are witnessing a high GI incidence rate due to increasing obesity in the adult population and less consumption of dietary fibers. As per the Centers for Disease Control and Prevention, in 2018, the number of visits to physician offices with the digestive system's diseases as the primary diagnosis was 22.4 million in the US. The incidence and prevalence of GI disorders are higher in the adult and elderly population. As the population ages, the disease burden is expected to increase. The GI disorders, such as inflammatory bowel diseases, Crohn’s disease, and ulcerative colitis, are common, chronic inflammatory conditions that affect a vast population worldwide. This is due to a sedentary lifestyle, changing dietary habits, stress, and other factors. The incidence and prevalence of IBS have increased in the last few decades worldwide. As per the International Foundation for Gastrointestinal Disorders, Inc., IBS is the most common functional GI disorder with a prevalence rate of 10–15% globally. Also, it is one of the most common conditions for a visit to a doctor. There are around 2.4–3.5 million physician visits for IBS annually in the US. The cost of direct medical expenses and indirect costs associated with loss of productivity and work absenteeism due to IBS is estimated to be around US$ 21 billion annually.
The report is inclusive of product type outlook, application spectrum, end-use outlook, technology landscape, regional market analysis, and competitive overview.
Geographic Segment Covered in the Report:
The Gastrointestinal Drugs Market report provides information about the market area, which is further subdivided into sub-regions and countries/regions. In addition to the market share in each country and sub-region, this chapter of this report also contains information on profit opportunities. This chapter of the report mentions the market share and growth rate of each region, country, and sub-region during the estimated period. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Gastrointestinal Drugs market in these regions.
TABLE OF CONTENTS
- Introduction
- Key Takeaways
- Research Methodology
- Gastrointestinal Drugs Market Landscape
- Gastrointestinal Drugs Market - Key Market Dynamics
- Gastrointestinal Drugs Market - Global Market Analysis
- Gastrointestinal Drugs Market - Revenue And Forecasts To 2028 - Type
- Gastrointestinal Drugs Market - Revenue And Forecasts To 2028 - Application
- Gastrointestinal Drugs Market Revenue And Forecasts To 2028 - Geographical Analysis
- Industry Landscape
- Gastrointestinal Drugs Market, Key Company Profiles
- Appendix
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, and Chemicals
Contact Us:
If you have any queries about this report or if you would like further information, please
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek